Healthcare and Medical

home | healthcare and medical | company profile

£265.00
Report Delivery: Via Email
Alerts
Change Currency EuroUSDGBP

Labopharm Inc - Premium Company Profile (Datamonitor)

  • Market: Healthcare and Medical
  • Published Date: 24/12/2007
  • Report Title: Labopharm Inc - Premium Company Profile
  • Table of Contents: View Table of Contents
  • Report Type: Company Profile
  • Country: Global
  • Number of Pages: 55
Introduction

Labopharm, formerly known as Centre de Recherche Appliquee Pharmaceutique (CRAP), is a specialty pharmaceutical company optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies: Contramid and PNDS. . It is currently focusing on developing and commercializing its lead product candidate, Trazodone for the potential treatment of depression.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


  • Highlights

    Labopharm's primary focus is developing small molecule drugs for two therapeutic indications, pain and depression. The company currently has one marketed product, Tramadol, indicated for moderate to severe pain, in Europe and Canada through its marketing partners. Trazodone, indicated for depression is currently in Phase III clinical development.

    The company's total revenues increased at a CAGR of 102.9% during 2002-2006, from $0.8 million to $14 million. This represents an absolute total growth of +$13.1 million for total revenues during the same period. License, collaboration and other revenues are a major contributor to revenue growth by contributing +$7.1 million.

    The company's biggest contributor to sales growth out to 2010 again will be revenues from license, collaboration and other. Revenues from license, collaboration and other are expected to increase from $8 million in 2006 to $75 million in 2010, recording an absolute growth of +$67 million.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization
  • £265.00   Share Report
     
    Alerts  

    Purchase Information

    There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.

    Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.

    Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.

    Worldpay Logo
    Chancy Currency EUR USD GBP
    Customer Area
    English Italian Spanish French German Russian Chinese Arabic